• Klann et al. (2017). CRISPR–Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome. Nat. Biotechnol.
• Wright, and Sanjana (2016). CRISPR Screens to Discover Functional Noncoding Elements. Trends Genet.
• Sanjana (2016). Genome-scale CRISPR pooled screens. Anal. Biochem.
• Thakore et al. (2016). Editing the epigenome: technologies for programmable transcription and epigenetic modulation. Nat. Methods.
• Thakore et al. (2015). Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. Nat. Methods.
• Romanoski et al. (2015). Exploiting genomics and natural genetic variation to decode macrophage enhancers. Trends Immunol.
• Köferle et al. (2015). Brave new epigenomes: the dawn of epigenetic engineering. Genome Med.
• Hilton et al. (2015). Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nat. Biotechnol.
• Konermann et al. (2014). Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature.
• Gilbert et al. (2014). Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell.
• Heller et al. (2014). Locus-specific epigenetic remodeling controls addiction- and depression-related behaviors. Nat. Neurosci.
• Lam et al. (2014). Enhancer RNAs and regulated transcriptional programs. Trends Biochem. Sci.
• Voigt, and Reinberg (2013). Epigenome editing. Nat. Biotechnol.
• Maeder et al. (2013). Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins. Nat. Biotechnol.
• Mendenhall et al. (2013). Locus-specific editing of histone modifications at endogenous enhancers. Nat. Biotechnol.